CAMBRIDGE, MA – On March 8, Biogen Inc. announced that its Board of Directors had elected Caroline Dorsa as the Chair of the Board, effective immediately after the Company’s 2023 Annual Meeting of Stockholders, scheduled for June 14, 2023. Dorsa will replace Stelios Papadopoulos, PhD, who had earlier announced that he would not seek reelection to the Board at the Annual Meeting.

Dr. Papadopoulos stated: “The entire Board holds Caroline in high esteem and recognizes her significant contributions during her 13-year tenure and as the Chair of our Audit Committee, where she has demonstrated exceptional judgment, integrity, and dedication.”

He added, “It has been an honor to serve on the Board of such a vital, purpose-driven company that has delivered numerous groundbreaking medicines and therapies, which have enhanced the lives of patients all over the world. I am stepping down with the confidence that the Board will be in very capable hands under Caroline’s exceptional leadership.”

Dorsa joined the Biogen Board in 2010. She served as the Executive Vice President and Chief Financial Officer of Public Service Enterprise Group, Inc., a diversified energy company, from 2009 until her retirement in 2015, and was a member of its Board of Directors from 2003 to 2009. Prior to that, she held various financial and operational roles over her 21-year career at Merck & Co, including Senior Vice President for Global Human Health, Strategy and Integration, as well as Vice President and Treasurer.

Dorsa stated, “Stelios has overseen a period of exceptional growth and transformation. The Board and Biogen have greatly benefited from his expertise, intelligence, and outstanding leadership.”

She went on to say, “It is an honor to be part of such a skilled and diverse Board. I am excited to collaborate with the company’s leadership to build upon Stelios’s legacy and continue to provide significant therapies for patients and value for our shareholders. Biogen is at an exciting juncture, and I believe that the company is well-positioned to achieve long-term sustainable growth.”

Christopher A. Viehbacher, President and Chief Executive Officer of Biogen, said, “On behalf of everyone at Biogen, I want to express our deepest gratitude to Stelios for his unwavering dedication and visionary leadership, which transformed Biogen into a global biotechnology powerhouse. Under his guidance, Biogen developed groundbreaking therapies such as TECFIDERA for multiple sclerosis, SPINRAZA for spinal muscular atrophy, and collaborated on the co-development of ADUHELM and LEQEMBI for Alzheimer’s disease. Caroline possesses extensive knowledge of our company, and I am thrilled to continue collaborating with her and the rest of the Board to promote shareholder growth and deliver innovative treatments for the patients we serve.”

About Biogen

Established in 1978, Biogen is a prominent global biotechnology company that has led the way in several breakthrough innovations, including a wide range of medications for multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two jointly developed treatments aimed at addressing a key characteristic of Alzheimer’s disease. Biogen is currently progressing a pipeline of promising new therapies across neurology, neuropsychiatry, specialized immunology, and rare diseases while maintaining a strong focus on its purpose of serving humanity through science and contributing to a healthier, more sustainable, and equitable world.